Comparing DCBs in De Novo CAD: Drugs, Design Matter
At TCT 2023, two studies of sirolimus- vs paclitaxel-coated devices reached different conclusions about 6-month late lumen loss.
Source: tctmd.com
📰 Sequent Please News
Sequent Please News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Sequent Please. Real-time updates on events, politics, business and more.
Comparing DCBs in De Novo CAD: Drugs, Design Matters
At TCT 2023, two studies of sirolimus- vs paclitaxel-coated devices reached different conclusions about 6-month late lumen loss.
Source: tctmd.com
Long-term Data Support Paclitaxel-Coated Balloons for In-Stent Restenosis
The DCB performed as well as a DES at 10 years, with similar rates of TLR despite leaving nothing behind in the artery.
United States P Sebastian Kufner Sebastian Kufner Domitilla Gentile Deutsches Herzzentrum Mario Iannaccone
Source: tctmd.com
TRANSFORM 1 Aufnahme abgeschlossen: Eine wichtige RCT, dazu bereit, den DCB-Angioplastie-Mechanismus neu zu definieren
/PRNewswire/ -- Concept Medical gibt den erfolgreichen Abschluss der TRANSFORM 1 RCT bekannt (TReAtmeNt of Small coronary vessels: Randomized controlled trial...
Bernardo Cortese Brown Melsungen Magictouch Scb Our Department Initiative Of Concept Corrib Core Lab
Source: prnewswire.com
Concept Medical Inc.: Much Awaited, Much Needed: TRANSFORM II Randomized Controlled Trial, by Fondazione RIC, gets rolling
MILANO, Italy, Jan. 28, 2022 /PRNewswire/ -- FONDAZIONE Ricerca e Innovazione Cardiovascolare, Milano, focused on cardiovascular research, reports the first patient enrolment of the TRANSFORM
Source: finanznachrichten.de
Much Awaited, Much Needed: TRANSFORM II Randomized Controlled Trial, by Fondazione RIC, gets rolling
/PRNewswire/ -- FONDAZIONE Ricerca e Innovazione Cardiovascolare, Milano, focused on cardiovascular research, reports the first patient enrolment of the...
Source: prnewswire.com
Much Awaited, Much Needed: TRANSFORM II Randomized Controlled Trial, by Fondazione RIC, gets rolling
MILANO, Italy, Jan. 28, 2022 /PRNewswire/ -- FONDAZIONE Ricerca e Innovazione Cardiovascolare, Milano, focused on cardiovascular research, reports the first patient enrolment of the TRANSFORM II Randomized Controlled Trial (Sirolimus-coated Balloon Versus Drug-eluting Stent in Native Coronary Vessels) setting in motion a crucial trial in the Native Coronary Vessel Treatment domain. TRANSFORM II RCT, determined to explore and...
Source: asiaone.com
Drug-Eluting Balloons (DEBs) Market to Record an Incremental Growth of USD 476.64 Million
Share this article Share this article NEW YORK, April 22, 2021 /PRNewswire/ -- The drug-eluting balloons (DEBs) market is expected to grow by USD 476.64 million during 2020-2024, according to Technavio. The report offers a detailed analysis of the impact of the COVID-19 pandemic on the drug-eluting balloons (DEBs) market in optimistic, probable, and pessimistic forecast scenarios. Enterprises will go through the Response, Recovery, and Renew phases. Technavio has announced its latest market r...
Source: prnewswire.com